CD8^+PD-1^+ to CD4^+PD-1^+ ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers

Boris Duchemann, Marie Naigeon, Edouard Auclin, Roberto Ferrara, Lydie Cassard, Jean-Mehdi Jouniaux, Lisa Boselli, Jonathan Grivel, Aude Desnoyer, François-Xavier Danlos, Laura Mezquita, Caroline Caramella, Aurelien Marabelle, Benjamin Besse

ABSTRACT

Background Programmed cell death protein-1 (PD-1) expression has been associated with activation and exhaustion of both the CD4 and CD8 populations in advanced non-small cell lung cancer (aNSCLC). Nevertheless, the impact of the balance between circulating CD8^+PD-1^+ and CD4^+PD-1^+ in patients treated with immune checkpoint blockers (ICB) is unknown.

Methods The CD8^+PD-1^+ to CD4^+PD-1^+ ratio (PD-1-Expressing Ratio on Lymphocytes in a Systemic blood sample, or ‘PERLS’) was determined by cytometry in fresh whole blood from patients with aNSCLC before treatment with single-agent ICB targeting PD-1 or programmed cell death-ligand 1 (PD-L1) (discovery cohort). A PERLS cut-off was identified by log-rank maximization. Patients treated with ICB (validation cohort) or polychemotherapy (control cohort) were classified as PERLS+/− (above/below cut-off). Circulating immune cell phenotype and function were correlated with PERLS. A composite score (good, intermediate and poor) was determined using the combination of PERLS and senescent immune phenotype as previously described in aNSCLC.

Results In the discovery cohort (N=75), the PERLS cut-off was 1.91, and 11% of patients were PERLS+. PERLS + correlated significantly with median progression-free survival (PFS) of 9.63 months (95% CI 7.82 to not reached (NR)) versus 2.69 months (95% CI 1.81 to 5.52; p=0.03). In an independent validation cohort (N=36), median PFS was NR (95% CI 7.9 to NR) versus 2.00 months (95% CI 1.3 to 4.5; p=0.04) for PERLS+ and PERLS−, respectively; overall survival (OS) followed a similar but non-significant trend. In the pooled cohort (N=111), PERLS + correlated significantly with PFS and OS. PERLS did not correlate with outcome in the polychemotherapy cohort. PERLS did not correlate with clinical characteristics but was significantly associated with baseline circulating naive CD4^+ T cells and the increase of memory T cells post-ICB treatment. Accumulation of memory T cells during treatment was linked to CD4^+ T cell polyfunctionality. The composite score was evaluated in the pooled cohort (N=68). The median OS for good, intermediate and poor composite scores was NR (95% CI NR to NR), 8.54 months (95% CI 4.96 to NR) and 2.42 months (95% CI 1.97 to 15.5; p=0.001), respectively. The median PFS was 12.60 months (95% CI 9.63 to NR), 2.58 months (95% CI 1.74 to 7.29) and 1.76 months (95% CI 1.31 to 4.57; p<0.0001), respectively.

Conclusions Elevated PERLS, determined from a blood sample before immunotherapy, was correlated with benefit from PD-(L)1 blockers in aNSCLC.

INTRODUCTION

Despite recent major advances in therapeutic including targeted therapy and immunotherapy lung cancer has a particularly poor prognosis. For patients with advanced non-small cell lung cancer (aNSCLC), programmed cell death-ligand 1 (PD-L1)/programmed cell death protein-1 (PD-1) blockers administered alone or in association with chemotherapy are now the backbone of treatment in most clinical settings. PD-L1 expression on biopsy tumorous cells is the only biomarker currently used to select patients for potential sensitivity to immune checkpoint inhibitors (ICB). Nevertheless these biomarkers suffer several well-known limitations, including result variability related to technical issues, the need for tumor biopsy tissue, and the lack of host immune status evaluation.

Several circulating biomarkers have been studied as potential biomarkers. Among them, PD-1 expression on circulating immune T cells is thought to reflect the activation of the PD-1/PD-L1 axis and consequently the patient’s sensitivity to ICB. Studies showed promising results using circulating lymphocytes as biomarkers in patients with aNSCLC. Baseline CD8^+PD-1^+ T cells have been described as being associated with good prognosis with ICB. Similarly, early CD8^+PD-1^+
T cell proliferation under ICB has been associated with good prognosis. On the other hand, CD4+PD-1+ has been correlated with worse outcome of treatment naïve patients eligible for standard of care chemotherapy or tyrosine kinase inhibitors9 and with poor clinical outcome after anti-PD-L1 treatment. However, these evaluations are not consistently reported, with the absence of a validation and control groups.

We hypothesized that a combination of PD-1 expression on both circulating CD4+ and CD8+ T cells before ICB treatment could be able to guide therapy for patients with aNSCLC. Thus, we explored the CD8+PD-1 to CD4+PD-1 ratio (PERLS) as a predictive biomarker of response to PD-(L)1 blockers.

**MATERIALS & METHODS**

**Patients and treatments**

Data were collected from consecutive patients with aNSCLC enrolled in three prospective studies: CEC-CTC (NCT02666612, (discovery ICB cohort)) between March 2017 and June 2018, MSN (NCT02105168, polychemotherapy (PCT) control cohort) between September 2017 and July 2018, and PREMIS (NCT03984318) (validation ICB cohort) between July 2019 and March 2020. Fresh whole blood samples were analyzed (maximum 10 samples over 3 years for each patient). The ethics committee approved these studies. All patients provided written informed consent.

In the ICB discovery and validation cohorts, patients with aNSCLC were treated with single-agent ICB (anti-PD-1 or anti-PD-L1). In the control cohort, treatment naïve patients with aNSCLC received PCT. To be eligible, patients had to be 18 years or older, with histologically or cytologically confirmed stage III or IV NSCLC and have available fresh blood samples collected immediately prior to PCT and/or single agent ICB. The pooled cohort combined patients from the discovery and the validation cohorts.

All radiological evaluations were centrally reviewed by a senior radiologist. Tumor response was assessed according to Response Evaluation Criteria in Solid Tumors V.1.1. Objective response rate (ORR) was the sum of complete response (CR) and partial response (PR), disease control rate (DCR) was the sum of CR, PR and stable disease (SD). Durable clinical benefit (DCB) was defined as CR and PR, plus SD of more than 6 months otherwise patients were considered as no-DCB.

**Flow cytometry**

The procedure to perform blood immune phenotyping on fresh whole blood samples has been described elsewhere. Flow cytometry antibodies and fluorochromes used are described in the online supplemental methods and table S1. Two PD-1 clones were used; PD-1.3 from Beckman (first part; N=35) and MIH4 from eBioscience (second part; N=40) which recognize different epitopes of PD-1. As patients were treated with PD-1 inhibitor, follow-up with the PD-1.3 antibody was not possible due to competition with the therapeutic antibody. In the second part of the cohort, the MIH4 clone was selected as it does not compete with therapeutic PD-1 inhibitors, thereby allowing follow-up. Result of ratio was reproducible in patients with both antibodies.

Senescent immune phenotype (SIP) was defined as positive (SIP+) when the percentage of CD28–CD57–KLRG1+ among CD8+ T cells was over 39.5%, as published elsewhere. A differentiation panel allowed phenotypic characterization of CD4+ T-helper and CD8+ cytotoxic cell subsets particularly their differentiation status (naïve (TN; CD45RACCR7), effector memory (TEM; CD45RA–CCR7), central memory (TCM; CD45RACCR7) and terminally differentiated (TEMRA; CD45RACCR7) T cells). CD4+CD127lo/–CD25high defined regulatory CD4+ T cells (Treg) otherwise CD4+ T cells were considered as conventional T cells (Tconv). These flow cytometry panels as well as their gating strategies has already been published.

Intracellular staining of cytokines to determine the polyfunctionality of T cells was realized. Interferon (IFN) γ, tumor necrosis factor (TNF)α, interleukin (IL)-9, IL-4 and IL-17A were monitored. Frozen peripheral blood mononuclear cells (PBMC) were used from the discovery cohort prior to ICB administration (N=25) and after 2 months of treatment when the sample was received (N=18). Polyfunctionality was defined as the ability for a lymphocyte to secrete more than one cytokine (two or above). DurActive and DuraClone IF T Helper Cell Tubes (Beckman Coulter) were used for cytokine assessment. DurActive tubes are ready-to-use cell activation mixture containing the phorbol ester, PMA (phorbol 12-myristate 13-acetate) and a calcium ionophore (Ionomycin). DuraClone IF T Helper Cell Tubes are preformulated, dried antibody panels of six markers in fluorochrome combinations that provide robust population identification, including CD3-AF750, CD4-APC, IL-4-PC7, IL-17A-PE, IFN-γ-FITC. A drop of IL-9-PE (BioLegend) and TNF-αA700 (Beckman Coulter) was added in the DuraClone IF T Helper Cell Tubes. For the cytokine staining of PBMCs, 50 µL suspension of PBMCs (containing ~5×10⁵ cells) were directly introduced into the DurActive tube, vortexed for 6–8s and incubated at 37°C for 3 hours. After the 3hours incubation, 25 µL of buffer R1 (PerFix-nc fixative reagent, Beckman Coulter) was added and incubated for 15 min at room temperature. After washing with 2 mL 1x phosphate-buffered saline, 25 µL of fetal bovine serum and 300 µL of buffer R2 (PerFix-nc permeabilizing reagent) were added and transferred to the DuraClone IF T Helper Cell Tube. Tubes were incubated 45 min at room temperature and 3 mL of R3 (final solution 1x in water) (PerFix-nc wash reagent, Beckman Coulter) was added. After centrifugation and aspiration of the supernatant, 500 µL of R3 (final solution 1x in water) was added. After vortex, samples were ready for FACS acquisition. Flow cytometry data were analyzed using Kaluza.
Flow Cytometry Software (Beckman Coulter) by a single operator, blinded to the patients’ clinical data. Graphs for flow cytometry data were produced using GraphPad Prism V.7.0 or V.8.0 (GraphPad Software, San Diego, California, USA). Online supplemental figure S1 illustrates dot plots data and gating strategies of immune cell populations.

**Statistical analysis**

Median values (IQR) and frequencies (percentage) were calculated for descriptions of continuous and categorical variables, respectively. Means and proportions were compared using the Student’s t-test and χ² test (or Fisher’s exact test, if appropriate), respectively. Overall survival (OS) was defined as the time between ICB initiation and death from any cause. Progression-free survival (PFS) was defined as the time between ICB initiation and progression or death, whichever occurred first. OS and PFS were estimated using the Kaplan-Meier method. T

Follow-up was calculated using the reverse Kaplan-Meier method. To better stratify PFS risk, an optimal cut-off for the PD-1⁺ Expression Ratio on Lymphocyte on Systemic sample, or ‘PERLS’ (CD8⁺PD-1⁺/CD4⁺PD-1⁻) was obtained with the log-rank maximization method. The ratio CD8⁺PD-1⁻/CD4⁺ PD-1⁺, expressed as a percentage of total CD8⁺ or total CD4⁺, respectively, was assessed by flow cytometry in blood and patients were classified as having a high or low PERLS ratio (PERLS⁺ or PERLS⁻). Analyses were reported according to REMARK guidelines for prognostic studies. 17 A composite PERLS score was determined based on ICB and SIP; as SIP⁺ is a marker associated with better OS without reaching significance, (online supplemental figure S2A). No significant difference was seen with the CD8⁺/CD4⁺ ratio (ie, not incorporating PD-1 expression) for either DCB or no-DCB (median 0.62 vs 0.71; p=0.66) (online supplemental figure S2B).

PERLS⁺ patients had significantly better median PFS (9.63 months 95% CI 7.82 to NR) versus 8.11 months (95% CI 6.31 to 18.00). PERLS was also associated with better OS without reaching significance, with median OS NR (95% CI 9.6 to NR) versus 8.11 months (95% CI 6.31 to 18.00).

**RESULTS**

**Patient characteristics**

PERLS ratio analyses were performed prior to treatment in 84 patients with aNSCLC in the discovery cohort. Of them, 76 then received at least one ICB infusion, had available cytometry data, and 75 were evaluable for response. Patient characteristics for the discovery cohort are presented in table 1. Median follow-up was 20.1 months (95% CI 16.9 to 31.2). Among 75 patients evaluable for response, the ORR was 25.3% (19/75), and the DCR was 53.3% (40/75), with 35 patients (46.7%) having progressive disease as a best response. Median PFS and OS were 3.68 months (95% CI 1.87 to 5.68), 9.40 months (95% CI 6.77 to 18.96), respectively.

In the PCT cohort, PERLS analysis was performed in 39 treatment-naïve patients with aNSCLC eligible for PCT. After a median follow-up of 6.0 months (95% CI 4.6 to 6.8), the ORR was 33.3% (13/39), and the DCR was 85.0% (33/39). Median PFS and OS were 4.99 months (95% CI 4.17 to not reached (NR)) and 7.10 months (95% CI 6.96 to NR), respectively.

In the validation cohort, PERLS analysis was performed in 36 treatment-naïve patients with aNSCLC eligible for ICB. Patient characteristics of this cohort are reported in online supplemental table S2. Median follow-up was 17.3 months (15.1–20.8). ORR was 25.0% (9/36), and DCR was 33.3% (12/36). Median PFS and OS were 2.5 months (95% CI 1.8 to 4.7) and 8.6 months (95% CI 3.2 to NR), respectively.

**PERLS cut-off, outcome and clinical characteristics**

**Discovery cohort**

As both CD8⁺PD-1⁺ and CD4⁺PD-1⁺ have been implicated in outcome with ICB in published data, we focused on the CD8⁺/CD4⁺PD-1⁺ ratio to define PERLS. In the ICB discovery cohort (n=75), the median PERLS value was 1.18. The cut-off for survival risk computed by log-rank maximization method was 1.91. In this cohort, 11% (8/75) of patients had PERLS >1.91 and were classified as high PERLS (PERLS⁺).

Patients with DCB had significantly higher PERLS than those without (mean 1.42 vs 0.89 p=0.0022) (online supplemental figure S2A). No significant difference was seen with the CD8⁺/CD4⁺ ratio (ie, not incorporating PD-1 expression) for either DCB or no-DCB (median 0.62 vs 0.71; p=0.66) (online supplemental figure S2B).

PERLS⁺ patients had significantly better median PFS (9.63 months 95% CI 7.82 to NR; p=0.03) compared with PERLS⁻ patients (2.69 months; 95% CI 1.81 to 5.52) (online supplemental figure S2C). High PERLS was also associated with better OS without reaching significance, with median OS NR (95% CI 9.6 to NR) versus 8.11 months (95% CI 6.31 to 18.00).

**Validation, pooled and control cohorts**

In the ICB validation cohort, PERLS was available for 36 patients. Median PERLS value was 0.93 (0.77–1.21). Using the cut-off of 1.91, patients with a high PERLS value had a median PFS of NR (95% CI 7.9 to NR) versus 2.0 months (95% CI 1.30 to 4.50; p=0.04) compared with patients with a low PERLS value. The same trend was found for median OS which was NR (95% CI NR to NR) versus 7.1 months (95% CI 3.1 to NR; p=0.09).

We then evaluated PERLS in the pooled cohort, discovery and validation cohorts (N=111). Patients with DCB had significantly higher PERLS values than patients with no-DCB (mean 1.43 vs 1.06; p=0.002) (figure 1A). This difference was not found for the CD8⁺/CD4⁺ ratio (mean ratio was 0.69 DCB vs 0.74 no-DCB; p=0.79) (figure 1B). PERLS⁺ patients had significantly longer median PFS compared with PERLS⁻ patients (9.63 months, 95% CI 7.82 to NR vs 2.20 months, 95% CI 1.81 to 4.50; p=0.004)
## Table 1 Patient characteristics in the discovery cohort

| Characteristic                              | All patients (N=75) | Low PERLS (N=67) | High PERLS (N=8) | P value |
|---------------------------------------------|---------------------|------------------|------------------|---------|
| Age in years, median (IQR)                 | 61 (55.5; 70.5)     | 61 (56; 71.5)    | 55.5 (52.75; 61.5)| 0.974   |
| Sex, n (%)                                  |                     |                  |                  |         |
| Female                                      | 35 (46.7)           | 32 (47.8)        | 3 (37.5)         | 0.716   |
| Male                                        | 40 (53.3)           | 35 (52.2)        | 5 (62.5)         |         |
| Smoking history, n (%)                      |                     |                  |                  |         |
| Never                                       | 8 (10.8)            | 6 (9.1)          | 2 (25)           | 0.396   |
| Former                                      | 39 (52.7)           | 35 (53.0)        | 4 (50)           |         |
| Active                                       | 27 (36.5)           | 25 (37.9)        | 2 (25)           |         |
| Missing                                      | •                    | •                | 0                |         |
| Histology, n (%)                            |                     |                  |                  |         |
| Adenocarcinoma                              | 61 (81.3)           | 53 (79.1)        | 8 (100)          | 0.535   |
| Squamous                                    | 11 (14.7)           | 11 (16.4)        | 0 (0)            |         |
| Other*                                       | 3 (4)               | 3 (4.5)          | 0 (0)            |         |
| TNM‡, n (%)                                 |                     |                  |                  |         |
| III                                          | 13 (17.3)           | 12 (17.9)        | 1 (12.5)         | *       |
| IV                                           | 62 (82.7)           | 55 (82.1)        | 7 (87.5)         |         |
| Tumor PD-L1 (% tumorous cells), n (%)        |                     |                  |                  |         |
| <1                                           | 10 (25)             | 8 (22.9)         | 2 (40)           | 0.654   |
| 1%–49                                        | 6 (15)              | 6 (17.1)         | 0 (0)            |         |
| >49                                          | 24 (60)             | 21 (60)          | 3 (60)           |         |
| Missing                                      | 35                  | 32               | †                |         |
| Main molecular alteration, n (%)            |                     |                  |                  |         |
| K-RAS                                       | 16 (37.2)           | 16 (37.2)        | 0 (0)            | *       |
| Wild-type‡                                   | 18 (41.9)           | 18 (41.9)        | 0 (0)            |         |
| Targetable§                                 | 9 (20.9)            | 9 (20.9)         | 0 (0)            |         |
| Missing                                      | •                    | •                | 0                |         |
| N metastatic sites, n (%)                   |                     |                  |                  |         |
| ≤2                                           | 54 (72)             | 49 (73.1)        | 5 (62.5)         | 0.679   |
| >2                                           | 21 (28)             | 18 (26.9)        | 3 (37.5)         |         |
| ECOG PS, n (%)                              |                     |                  |                  |         |
| 0–1                                          | 65 (86.7)           | 57 (85.1)        | 8 (100)          | 0.587   |
| †                                            | 10 (13.3)           | 10 (14.9)        | 0 (0)            |         |
| Lines of prior therapy, n (%)               |                     |                  |                  |         |
| 0                                            | 6 (8)               | 4 (6.0)          | 2 (25)           | 0.121   |
| >1                                           | 69 (92)             | 63 (94.0)        | 6 (75)           |         |
| Prior chemotherapy, n (%)                   |                     |                  |                  |         |
| No                                           | 6 (8)               | 4 (6.0)          | 2 (25)           | 0.121   |
| Yes                                          | 69 (92)             | 63 (94.0)        | 6 (75)           |         |
| Prior radiotherapy, n (%)                   |                     |                  |                  |         |
| No                                           | 51 (68)             | 45 (67.2)        | 6 (75)           | *       |
| Yes                                          | 24 (32)             | 22 (32.8)        | 2 (25)           |         |
| dNLR ≥3, n (%)                              |                     |                  |                  |         |
| No                                           | 36 (60)             | 30 (57.7)        | 6 (75)           | 0.457   |
| Yes                                          | 24 (40)             | 22 (42.3)        | 2 (25)           |         |
| Missing                                      | 15                  | 15               | 0                |         |
| IrAEs (grade ≥3 or requiring CS¶)           |                     |                  |                  |         |
| Yes                                          | 5 (67)              | 4 (6)            | 1 (13)           | 0.437   |
| No                                           | 70 (33)             | 63 (94)          | 7 (87)           |         |
| LDH≥ULN, n (%)                              |                     |                  |                  |         |
| No                                           | 20 (47.6)           | 17 (46.0)        | 3 (60)           | 0.656   |
| Yes                                          | 22 (52.4)           | 20 (54.1)        | 2 (40)           |         |
| Missing                                      | 33                  | 30               | †                |         |
| LIPI score**, n (%)                          |                     |                  |                  |         |
| Good                                         | 10 (24.4)           | 8 (22.2)         | 2 (40)           | 0.482   |
| Intermediate                                 | 22 (53.7)           | 19 (52.8)        | 3 (60)           |         |
| Poor                                         | 9 (22.0)            | 9 (25)           | 0 (0)            |         |
| NA                                           | 34                  | 31               | †                |         |

*Large cell lung cancer, non-small cell lung cancer, not otherwise specified.
†TNM stage eighth edition.
‡Absence of EGFR mutations, KRAS, ALK, ROS1 rearrangements.
§EGFR mutations, ALK, ROS1 rearrangement, HER2 mutations, MET alterations, BRAF mutations. Radiotherapy (including stereotactic radiotherapy) on any site (including bone or central nervous system).
¶Two patients with grade 3 colitis, one with grade 3 pneumonitis and two patients with grade 2 pneumonitis requiring cortico-steroids treatment.
**LIPI high: dNLR >3 and LDH >ULN; LIPI intermediate: dNLR <3 and LDH >ULN or dNLR >3 and LDH <ULN; LIPI low: dNLR <3 and LDH <ULN.
dNLR, derived neutrophil to lymphocyte ratio (neutrophils/leukocytes – neutrophils); IrAEs, immune related adverse events; LDH, lactate dehydrogenase; LIPI, lung immune prognostic index; PD-L1, programmed cell death-ligand 1; PS, performance status; TNM, tumour, node, metastases; ULN, upper limit of normal.

---

**LIPI high:** dNLR >3 and LDH >ULN; **LIPI intermediate:** dNLR <3 and LDH >ULN or dNLR >3 and LDH <ULN; **LIPI low:** dNLR <3 and LDH <ULN.

dNLR, derived neutrophil to lymphocyte ratio (neutrophils/leukocytes – neutrophils); IrAEs, immune related adverse events; LDH, lactate dehydrogenase; LIPI, lung immune prognostic index; PD-L1, programmed cell death-ligand 1; PS, performance status; TNM, tumour, node, metastases; ULN, upper limit of normal.
Open access

Duchemann B, et al. J Immunother Cancer 2022;10:e004012. doi:10.1136/jitc-2021-004012

Figure 1  PERLS is associated with disease clinical benefit (DCB) in advanced non-small cell lung cancer treated with immune checkpoint blockers. Blood T cells populations from patients included in the discovery and the validation cohorts, that is, pooled cohort. (A) PERLS ratio from the pooled cohort in patients with no-DCB and DCB. (B) As in (A) but with the CD8+/CD4+ ratio. (C) As in (A) but with CD8+ PD-1+/Tconv PD-1+ ratio. (D) As in (A) but with the CD8+PD-1+/TregPD-1+ ratio. (E) PFS according to PERLS. (F) Overall survival according to PERLS. PD-1, programmed cell death protein-1; PFS, progression-free survival.

(figure 1C). High PERLS was also associated with better OS (NR, 95% CI NR to NR vs 7.98 months, 95% CI 5.95 to 14.90; p=0.02) (figure 1D).

To assess the predictive or prognostic role of PERLS, we evaluated a control cohort of patients treated with PCT without ICB (N=39). There was no significant difference in PFS for patients with high or low PERLS (5.91 months, 95% CI 4.17 to NR vs 4.83 months, 95% CI 3.84 to NR; p=0.20) (online supplemental figure S3).

PERLS and clinical characteristics

Clinical and pathological characteristics of both the discovery and validation cohorts are summarized in table 1 and online supplemental table S2 for the whole cohort and according to PERLS status. No clinical characteristics were associated with the PERLS ratio, notably PD-L1 (by immunohistochemistry), mutational status or tumor burden. Nine patients had an oncogenic addiction, including four patients with BRAF (two patients with V600E mutation), one patient with EGFR activating mutation, two patients with HER2 mutation, one patient with ROS1, and one patient with RET rearrangement. Patient with EGFR mutation and one patient with BRAF V600E were pretreated with tyrosine kinase inhibitor before ICB. All these patients with oncogenic mutation had a low PERLS.

Regarding immune-related adverse events (IrAEs) we focused on the grade ≥3 or those of grade 2 but requiring medical intervention including suspension or stop of ICB and corticosteroids treatment. There was no difference between the low and high PERLS groups in the discovery or validation cohort.

PERLS correlation with lymphocyte phenotypic profile

At the time of data analysis, a differentiation panel and a Treg panel were available for 75 and 42 patients, respectively, in the discovery cohort. Evaluation after 2 months of ICB treatment (D60) was available in 24 of the 75 patients (32%) for PERLS and in 43 of the 75 patients (57%) for the differentiation panel.
PERLS and Treg
Since a higher CD8⁺PD⁻1⁺/CD4⁺PD⁻1⁺ ratio is associated with better prognosis, we wondered whether increased/decreased immunosuppression could influence this outcome. To answer this question, we monitored Treg in a subcohort of 42 patients and we analyzed T_cone (non-Treg CD4⁺ T cells) and T_reg separately. Interestingly, both CD8⁺PD⁻1⁺/T_cone-PD⁻1⁻ and CD8⁺PD⁻1⁺/T_reg-PD⁻1⁺ ratio were higher in patients with DCB compared with patients with no-DCB (p=0.004 and p=0.007, respectively; figure 1E–F). This suggests that a greater accumulation of CD4⁺PD⁻1⁺ relative to CD8⁺PD⁻1⁺ is deleterious irrespective of the regulatory or non-regulatory phenotype of CD4⁺ T cells.

PERLS, T cell differentiation and polyfunctionality
PERLS was positively correlated with the proportion of blood naïve CD4⁺ T cells (CD45RA⁺CCR7⁺) at baseline (r=0.60; p<0.001) (figure 2A and B). The proportion of naïve CD4⁺ T cells was not correlated with DCB (figure 2C), however the negative evolution (decrease) between D60 and D0 of naïve CD4⁺ T cells was associated with DCB (figure 2D, left panel). Interestingly, only the positive evolution (increase in memory T) between D60 and D0 of memory CD8⁺ T cells was associated with DCB (figure 2D, right panel). This suggests that differentiation from naïve to memory T cells was associated with clinical benefit. In accordance with this observation, an increase of cytokine production in CD4⁺ T cells at D60 was
observed only in patients benefiting from the treatment (online supplemental figure S4B) and not in patients with no-DCB (online supplemental figure S4A). Moreover, in patients with DCB, polyfunctional CD4\(^+\) T cells were significantly more frequent at D60 compared with patients with no-DCB (online supplemental figure S4D). No such difference could be observed at D0 suggesting that polyfunctional T cells were induced by ICB treatment (online supplemental figure S4C). We next evaluated if PERLS could be linked to the induction of memory T cells after ICB treatment. Among the 42 patients where both data were collected, PERLS was positively correlated with the positive evolution (increase) of memory T cells (figure 2E). This correlation was more significant for the evolution of memory CD8\(^+\) T cells (\(r=0.46; p=0.05\); N=18) and CD4\(^+\) (\(r=0.58, p=0.01; N=18\)) T cells at D60 was positively associated with the polyfunctionality of T cells after ICB treatment (figure 2F), no such observation could be depicted at D0 (data not shown).

PERLS and senescence

Based on a previous study showing an association between SIP and worse prognosis,\(^{13}\) we evaluated our population according to a composite prognostic score using the pooled discovery and validation cohort. PERLS was available for 111 patients, 13 of whom (11.2%) had a high PERLS. Overall, 69 patients had a SIP evaluation, 19 of whom (28.0%) were SIP\(^+\). PERLS and SIP were available in 68 patients, with 8 (11.8%), 18 (26.5%) and 42 (61.8%) having good, poor or intermediate composite score, respectively. In the overall population, PERLS alone had a specificity and sensitivity of 38.9% and 93.5%, respectively, to detect responders. SIP and PERLS were inversely correlated (figure 3A). As described in our previous study,\(^{13}\) in the pooled cohort, SIP\(^+\) was associated with longer median PFS of 5.06 months (95% CI 2.0 to 12.0; \(p<0.0001\) for SIP\(^-\)) versus 1.82 months (95% CI 1.31 to 4.5) and longer median OS of 20.80 (95% CI 7.80 to NR; \(p=0.002\)) versus 2.42 months (95% CI 2.17 to 15.5). Considering the composite score, outcomes differed for the good, the intermediate and the poor composite score groups. Indeed, the median PFS was 12.6 months (95% CI 9.63- to NR) versus 2.58 months (95% CI 1.74 to 7.29) and 1.76 months (95% CI 1.31 to 4.57; \(p<0.0001\)) (figure 3C) and the median OS was not reach (95% CI NR to NR) versus 8.54 months (95% CI 4.96 to NR) and 2.42 months (95% CI 1.97 to 4.73; \(p=0.001\)), respectively. (figure 3D).

The c-index of this strategy was 0.627 for PFS and 0.646 for OS. Of note all patients in the good composite score group had a DCB (8/8). Only one patient with poor composite score had a DCB (1/18) (figure 3B). None of the 8 patients in the good composite score group died early (<3 months) compared with 24% in the intermediate composite score group (10/42 patients) and 56% of the poor composite score group (10/18; \(p=0.007\); online supplemental figure S3).

**DISCUSSION**

We describe here the predictive value of a preimmunotherapy ratio, CD8\(^-\)PD-1\(^+\)/CD4\(^-\)PD-1\(^+\) (PERLS) in blood samples, for patients with aNSCLC and treated with ICB. These results also shows that PERLS is associated with a naïve CD4\(^+\) T cells at baseline and suggest that the ability to accumulate memory T cells and polyfunctional CD4\(^+\) T cells during treatment is associated with better prognosis. Moreover, PERLS seemed to predict ICB response and not only prognosis since no such observation was made in the chemotherapy cohort.

Most of studies have focused on tumor-infiltrating lymphocytes (TILs) and other immune cells in the tumor microenvironment (TME). Many studies have shown that ICB efficacy was dependent on rejuvenation of TILs,\(^{18}\) CD8\(^+\) T cells from the invasive margin of the tumor.\(^{19}\) CD8\(^-\)PD-1\(^+\) TILs have been shown to be more tumor specific.\(^{20,21}\) PD-1\(^+\) TILs have been associated with better prognosis under ICBs.\(^{22}\) Nevertheless, there is increasing evidence suggesting that expansion and recruitment of peripheral T cells during ICB treatment may have a prominent role to play in disease progression.\(^{22}\) First, several studies have confirmed that intratumor T lymphocytes have limited expansion ability in melanoma.\(^{23,24}\) Second, some studies suggested that circulating T cells can be recruited, leading to a ‘clonal replacement’ rather than the rejuvenation of existing T cell clonotypes.\(^{24}\) T cell receptor (TCR) clonotype analysis in mice and humans have shown that new clonotypes appear in tumors during treatment and that some of these novel TIL clones can be recruited from peripheral sources.\(^{24}\) In another study, clonotypic expansion of effector-like T cells in tumor tissue, adjacent tissue and peripheral blood has been associated with better response to PD-(L)1 therapy. A recent study compared both single cell TCR sequencing and RNA sequencing on paired tumor and blood samples.\(^{25}\) In this study, CD8\(^+\) T cells that developed in tumors was preexisting in blood. These data support that in responsive patients, intratumor T cells are replenished with fresh, non-exhausted T cells, that originate from outside the tumor.\(^{25}\)

We focused on blood T cells and particularly PD-1\(^+\) expressing T lymphocytes. As in TME, circulating PD-1\(^+\) T cells have also been reported to be tumor-specific in melanoma.\(^{26}\) Notably, circulating and tumor infiltrating CD8\(^-\)PD-1\(^+\) shared a similar TCR repertoire suggesting that there is a relationship between circulating and infiltrating PD-1\(^+\) T lymphocytes.\(^{26}\) PD-1\(^+\) T cell in tumor-draining lymph nodes were also described as tumor-specific,\(^{27}\) and can interact closely with dendritic cells. In mice, the targeting of PD-L1-expressing dendritic cells in the tumor draining lymph node induced seeding of the tumor site with T cells, and improved tumor control.\(^{27}\) In a recent study, deeper characterization of exhausted CD8\(^+\) T
cells population was evaluated. This work highlighted the existence of a four-stage developmental hierarchy of exhausted CD8+ T cells. Two populations were progenitor (TCF1<sup>high</sup>Tox<sup>high</sup> and TCF1<sup>int</sup>Tox<sup>high</sup>), with TCF1<sup>high</sup>Tox<sup>high</sup> being quiescent and resident and able to convert to TCF1<sup>int</sup>Tox<sup>high</sup>. This conversion was associated with a delocalization from lymphoid residence to blood locations and a proliferation-driven transition to a third subpopulation TCF1<sup>neg</sup>εbet<sup>high</sup>Tox<sup>int</sup> that have similarities to circulating ‘effector-like’ cells. Finally TCF1<sup>neg</sup>εbet<sup>high</sup>Tox<sup>int</sup> could convert into TCF1<sup>neg</sup>εbet<sup>low</sup>Tox<sup>high</sup>Eomes<sup>high</sup> these terminally differentiated exhausted CD8+ T cells are absent from the blood but can accumulate in tumors. Interestingly, intermediate circulating ‘effector-like’ exhausted CD8+ T cells can be activated and proliferate under PD-(L)1 blockade while terminally exhausted CD8+ T cells...
We next explored the relationship between PERLS and multiple immune blood biomarkers. Only the proportion of naïve T cells at baseline was related to this ratio. Circulating naïve T cells are less frequent in patients with tumors than in healthy individuals. In previous studies, patients with metastatic melanoma treated with ICB and with a higher frequency of naïve CD4+ T cells at baseline were shown to better respond to ICB while non-responders have more differentiated CD4 effector memory at baseline. After immunotherapy there was a shift to greater differentiation of CD4+ and acquisition of more cytotoxic capacity for CD8+ cells in responder patients. This shift was not found after chemotherapy. Another study in patients with melanoma, showed that expansion of CD8+ cells with a cytotoxic profile was associated with response during ICB. Valpione et al describe the emergence during ICB treatment of a cytotoxic memory effector peripheral T cell subset only in responding-patients with melanoma. Of note, this T cell subset has been associated with effector T cells migrating from lymph nodes to the blood, suggesting that naïve T cell population, able to differentiate during ICB treatment is mandatory for an effective immune response. In line with this previous observation, PERLS was associated with the increase from D0 to D60 of memory T cells, this increase being associated with clinical benefit. This demonstrate that the differentiation from naïve to memory T cells was associated with clinical benefit, PERLS being linked to positive evolution of memory T cells.

Polifunctional activity, or the ability to produce several soluble factors at the single cell level, is a key factor of T cell effectiveness. Several studies demonstrated that polyfunctional capacity of T cells correlates with the immune control during viral infections or after vaccination. There is growing evidence in cancer-bearing hosts that T cell polyfunctionality may favor immunological control of the tumor. Recently, Imai and colleagues showed in mice that the presence of CD4+ T cells was mandatory for the generation of polyfunctional tumor-specific CD8+ T cells with long persistence in vivo resulting in enhanced tumor regression. T cell polyfunctional activity was associated with clinical response with different approach of immunotherapy such as CAR-T cells or anti–PD-1 after stereotactic body radiation therapy in a mouse model. In patients with melanoma treated by autologous TIL infusion, a subset of tumor-reactive CD8+ T cells, expressing PD-1 with polyfunctional features, accumulated over time. Another study has shown that NSCLC-reactive TILs can be polyfunctional. However, in our knowledge no data exist in patients with aNSCLC treated with ICB. In our study, we brought evidence that post-treatment polyfunctional CD4+ T cells are more frequent in patients with a favorable outcome. Since, polyfunctional T cells and the proportion of memory T cells after ICB were positively associated and PERLS associated with the induction of memory T cells, we believe that PERLS measured at baseline could reflect that the patient’s immune system will be able to shift towards a memory and polyfunctional T cell response.
Our group has recently proposed that SIP may be a biomarker associated with resistance to ICB. 15 PERLS inversely correlated with SIP. This is not surprising since SIP is mainly composed of terminally differentiated T cells. The composite score PERLS and SIP helped to identify a subpopulation of patients admittedly low (11.8%) but in whom the treatment was systematically effective. Thus, we propose that PERLS and SIP could be complementary tools, and together these two circulating biomarkers can accurately select patients benefiting from ICB monotherapy.

Taked together these results may suggest that PERLS that correlates with a naïve T cell, could reflect the capacity of T cells to differentiate and become polyfunctional during treatment, functional properties essential for a clinical benefit in patients treated with therapeutic monoclonal antibodies that target and block PD-(L)1 molecules.

Even though our study has strengths such as performed in a large cohort, with prospective acquisition of fresh whole blood immune data, with control and validation cohorts. Moreover, PERLS is a ratio with a better reliability regardless of the PD-1 clone used for flow cytometry thus easy to implement in routine practice across laboratories. We can also enumerate limitations. First, CD4 PD-1+ and CD8 PD-1+ population may represent a mixture of T cells and a deeper characterization should be carried out. Second, we did not explore their functional capacity or their tumor specificity this is lacking and currently part of our perspectives. We have only studied T cell polyfunctionality in a small number of patients, which makes the exploration of the direct link with the PERLS ratio very difficult.

In conclusion, we propose that PERLS reflects an immunological status necessary for therapeutic response in patients with aNSCLC. This ratio is determined before treatment using an ‘untouched’ whole blood sample and has few technical requirements. Further studies are needed to better decipher mechanisms underlying our observations, however our finding suggests that the use of therapies that promote CD4+ T cell amplification and activation or limit their exhaustion may be of interest in patients with aNSCLC.

Author affiliations
1Laboratoire d’Immunomonitoring en Oncologie, INSERM US23, CNRS UMS 3655, Gustave Roussy, Villejuif, Ile-de-France, France
2Faculté de médecine, Université Paris-Saclay, Saint-Aubin, Ile-de-France, France
3Faculté de Pharmacie, Université Paris-Saclay, Chatenay-Malabry, Ile-de-France, France
4Department of Oncology, Hôpital Européen Georges Pompidou Cancérologie, Paris, France
5Department of Medical Oncology, Thoracic Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, Italy
6LRTI, INSERM U1015, Gustave Roussy, Villejuif, Ile-de-France, France
7Département Innovations Thérapeutiques Essais Précoces, Institut Gustave-Roussy, Villejuif, Ile-de-France, France
8Medical Oncology Department, Hospital Clinic de Barcelona, Barcelona, Spain
9Department of Radiology, Groupe hospitalier Paris Saint-Joseph, Paris, Ile-de-France, France
10Department Innovations Thérapeutiques Essais Précoces, Institut Gustave-Roussy, Villejuif, Ile-de-France, France
11Département Innovations Thérapeutiques Essais Précoces, Gustave Roussy, Villejuif, Ile-de-France, France
12Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, Ile-de-France, France
13Comité de pathologie thoracique, Gustave Roussy Institute, Villejuif, Ile-de-France, France

Acknowledgements We thank Sarah MacKenzie for providing writing assistance.

Contributors BD: is guarantor for the overall content, participated in the research design, conducted the experiments, and wrote the first draft of the manuscript and implement modifications in the final version of the manuscript. MN: participated in the research design, conducted the experiments and revised the manuscript for critical intellectual content. EA: Software, formal analysis, methodology. RF: participated in the research design. LC: participated in the research design, supervision, and immune data analysis and revised the manuscript for critical intellectual content. J-MJ: immune data analysis and revised the manuscript for critical intellectual content. LB: conducted the experiments and immune data analysis. JG: conducted the experiments. AD: immune data analysis. F-XD: provided clinical data and study operations support and revised the manuscript for critical intellectual content. LM: data curation. CC: provided clinical data. AM: revised the manuscript for critical intellectual content. BB: conceived the project, provided clinical data, study operations support, and revised the manuscript for critical intellectual content. NC: conceived and supervised the project, wrote the final version of the manuscript and provided funding. All authors read and approved the final manuscript.

Funding This study was supported by Gustave Roussy Cancer Campus, Fondation Gustave Roussy, the Institut National de la Santé et de la Recherche Médicale (INSERM), the Centre National de la Recherche Scientifique (CNRS), SIRIC SOCRATE 2.0 (INCA-DGOS-INSERM, 12551); Direction General de l’Oeuvre de Soins (DGOS, TRANSLA 12-174). BD was financed by AP-HP.

Competing interests BD: speakers bureaus or educational events from Roche, Pfizer, AstraZeneca, Chiesi, Amgen, Lilly; support for attending meetings and/or travel from AZ, Pfizer, Oxyvie. MN: no competing interest to declare. EA: support for attending meetings and/or travel from: Mundipharma; lectures and educational activities: Sanofi Genzymes. RF: senior advisory board meetings for MSD. LC, J-MJ, LB, JG, AD, F-XD: no competing interest to declare. LM: sponsored research: Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Stillia, Invivata. Consulting, advisory role: Roche Diagnostics, Takeda, Roche. Lectures and educational activities: Bristol Myers Squibb, Tecnofarma, Roche, Takeda. Travel, Accommodations, Expenses: Bristol Myers Squibb, Roche. Mentorship program with key opinion leaders: funded by AstraZeneca. CC: no competing interest to declare. AM: senior advisory board meetings for MSD, BMS, AstraZeneca/MedImmune, Sanofi, Pfizer, Roche/Genentech, Merck Serono. Consulting services to Sanofi, Roche/Genentech. Speakers bureau of MSD, BMS, AstraZeneca/MedImmune, Sanofi, Roche/Genentech, Merck Serono. BB: sponsored research at Gustave Roussy Cancer Center 4D Pharma, AbbVie, Amgen, Aptitude Health, AstraZeneca, Beigene, Blueprint Medicines, BMS, Boehringer Ingelheim, Cellgene, Cergentis, Cristal Therapeutics, Daiichi-Sankyo, Eli Lilly, GSK, Invivata, Janssen, Onxeo, OSE immunotherapeutics, Pfizer, Roche-Genentech, Sanofi, Takeda, Tolero Pharmaceuticals. NC: sponsored research at Gustave Roussy Cancer Center from AstraZeneca, GSK, Roche, Sanofi, Cyttene Pharma, Gilead, Servier.

Patient consent for publication Not applicable.

Ethics approval This study was approved by the ethics committee of Gustave Roussy.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request. Authors agree to give data and materials supporting the results or analyses presented in their paper available upon reasonable request.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.
Open access

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and use and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Boris Duchemann http://orcid.org/0000-0003-0872-2983
Laura Mezquita http://orcid.org/0000-0003-0936-7338
Aurelien Marabelle http://orcid.org/0000-0002-5816-3019
Nathalie Chaput http://orcid.org/0000-0003-3968-8669

REFERENCES

1 Howlader N, Forjaz G, Mooradian MJ, et al. The effect of advances in lung-cancer treatment on patient mortality. N Engl J Med 2016;374:369-380.
2 Resmini J, Paolino F, Ahn MJ, et al. Immune checkpoint inhibitors in thoracic malignancies: review of the existing evidence by an IASLC expert panel and recommendations. J Thorac Oncol 2020;15:914-47.
3 Hirsch FR, McElhinny A, Stanford D, et al. Pd-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint Pd-L1 IHC assay comparison project. J Thorac Oncol 2017;12:208-22.
4 Shaverdan N, Lisberg AE, Bornayan K, et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-010 trial 1. Lancet Oncol 2017;18:895-903.
5 Duchemann B, Remon J, Naigone M, et al. Integrating circulating biomarkers in the immune checkpoint inhibitor treatment in lung cancer. Cancers 2020;12, doi: 10.3390/cancers12236253. [Epub ahead of print: 03 Dec 2020].
6 Mazzacchi G, Minini R, Zecca A, et al. Soluble PD-L1 and circulating CD8+PD+1 and NK cells encode a prognostic and predictive immune effector score in immunotherapy treated NSCLC patients. Lung Cancer 2020;148:1-11.
7 Kamphorst AO, Pilla IN, Yang S, et al. Proliferation of PD+1–CD8+ T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients. Proc Natl Acad Sci U S A 2017;114:4993–8.
8 Kim KH, Cho J, Ku BM, et al. The first-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors. Clin Cancer Res 2019;25:2144–54.
9 Arrieta O, Montes-Servin E, Hernandez-Martinez J-M, et al. Expression of PD-1/PD-L1 and PD-L2 in peripheral T-cells from non-small cell lung cancer patients. Oncotarget 2017;8:110894-2005.
10 Zheng H, Liu X, Zhang J, et al. Expression of PD-1 on CD8+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer. Oncotarget 2016;7:56233-40.
11 Mildner F, Sopper S, Amann A, et al. Systematic review: soluble immunological biomarkers in advanced non-small-cell lung cancer (NSCLC). Crit Rev Oncol Hematol 2020;143:102948.
12 Eisenhauer EA, Therasse P, Bogaras J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228–47.
13 Ferrara R, Naigone M, Auclin E, et al. Circulating T-cell Immunosenesence in patients with advanced non-small-cell lung cancer treated with single-agent PD-1/PD-L1 inhibitors or platinum-based chemotherapy. Clin Cancer Res 2021;27:492-503.
14 Ferrara R, Naigone M, Auclin E, et al. Immunosenescence (Immunosenescence (Gammonecosts)coreld) to PD-L1 inhibitors (O) and not to platinum-chemotherapy (PCT) in advanced non-small cell lung cancer (nNSCLC) patients (pts). Annals of Oncology 2019;30:ii7–8.
15 Pitoiset F, Cassard L, El Soufi K, et al. Deep phenotyping of immune cell populations by optimized and standardized flow cytometry analyses. Cytometry A 2018;93:793–802.
16 Hothorn T, Lausen B. On the Exact Distribution of Maximally Selected Rank Statistics. In: Social Science Research Network Report No : ID 3133711. Rochester, NY, 2002. https://papers.ssrn. com/abstract=3133711.
17 McShane LM, Altman DG, Sauerbrei W, et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005;97:1180–4.
18 Herbst RS, Soria J-C, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014;515:563-7.
19 Tumeh PC, Harvie CL, Yearley JH, et al. Pd-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014;515:568–71.
20 Gros A, Robbins PF, Yao X, et al. Pd-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors. J Clin Invest 2014;124:229-35.
21 Thommen DS, Koelzer VH, Herzig P, et al. A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. Nat Med 2018;24:994–1004.
22 Acharya N, Anderson AC. New clones on the block. J Immunother Cancer 2019;7:306–8.
23 Sade-Feldman M, Yzhak K, Bjongaard SL, et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell 2018;175:e20:998–1013.
24 Yost KE, Satpathy AT, Wells DK, et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat Med 2019;25:1251-9.
25 Wu TD, Madiredi S, de Almeida PE, et al. Peripheral T cell expansion predicts tumour infiltration and clinical response. Nature 2020;578:274–8.
26 Gros A, Parkhurst MR, Tran E, et al. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat Med 2016;22:433–8.
27 Dammeyer J, van Gulijk M, Mulder EE, et al. The PD-1/PD-L1 Checkpoint Restraints T cell Immunity in Tumor-Draining Lymph Nodes. Cancer Cell 2020;38:685-700.
28 Beltra J-C, Manne S, Abdel-Hakeem MS, et al. Developmental Relationships of Four Exhausted CD8+ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Mechanisms. Immunity 2020;52:825–41.
29 Wikby A, Ferguson F, Forsey R, et al. An immune risk phenotype, cognitive immunity, and survival in very late life: impact of allostatic load in Swedish octogenarian and nonagenarian humans. J Gerontol A Biol Sci Med Sci 2005;60:556–65.
30 Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkppoint pathway. N Engl J Med 2016;375:1767–78.
31 Spitzer MH, Carmi Y, Reicher-Flynn NE, et al. Systemic immunity is required for effective cancer immunotherapy. Cell 2017;168:e15:487–502.
32 Rice SJ, Liu X, Zhang J, et al. Advanced NSCLC patients with high IL-6 levels have altered peripheral T cell population and signaling. Lung Cancer 2019;131:58–61.
33 Gambichler T, Schröter U, Höxtermann S, et al. A brief communication on circulating PD-1-positive T-regulatory lymphocytes in melanoma patients undergoing adjuvant immunotherapy with nivolumab. J Immunother 2019;42:265–8.
34 Kamada T, Togashi Y, Tai C, et al. PD-1 regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. Proc Natl Acad Sci U S A 2019;116:9999–10008.
35 Manjarewicz-Orduno N, Menard LC, Kansal S, et al. Circulating T cell subpopulations correlate with immune responses at the tumor site and clinical response to PD1 inhibition in non-small cell lung cancer. Front Immunol 2018;9:1613.
36 Griffiths JI, Waller P, Pfleger LT, et al. Circulating immune cell phenotype dynamics reflect the strength of tumor-immune cell interactions in patients during immunotherapy. Proc Natl Acad Sci U S A 2020;117:16072–82.
37 Valpione S, Galvani E, Tweedy J, et al. Immune-awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy. Nat Cancer 2020;12:1-21.
38 Fairfax BP, Taylor CA, Watson RA, et al. Peripheral CD8+ T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma. Nat Med 2020;26:193–9.
39 Almeida JR, Price DA, Papagno L, et al. Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med 2007;204:2473–85.
40 Precopio ML, Betts MR, Panniro J, et al. Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8+ T cell responses. J Exp Med 2007;204:1405–16.
41 Darragh PA, Patel DT, De Luca PM, et al. Multifunctional Th1 cells derive a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007;13:843–50.
42 Imai N, Tawara I, Yamane M, et al. CD4+ T cells support polyfunctionality of cytototoxic CD8+ T cells with memory potential in immunological control of tumor. Cancer Sci 2020;111:1596–68.
43 Fossi J, Paczkowski HC, Prehn H-W, et al. Mutually polyfunctional anti-CD19 chimeric antigen receptor T cells are associated by copyright.
Open access

44 Wei J, Montalvo-Ortiz W, Yu L, et al. Sequence of αPD-1 relative to local tumor irradiation determines the induction of abscopal antitumor immune responses. Sci Immunol 2021;6:eabg0117.

45 Donia M, Kjeldsen JW, Andersen R, et al. PD-1+ Polyfunctional T Cells Dominate the Periphery after Tumor-Infiltrating Lymphocyte Therapy for Cancer. Clin Cancer Res 2017;23:5779–88.

46 De Groot R, Van Loenen MM, Guislain A, et al. Polyfunctional tumor-reactive T cells are effectively expanded from non-small cell lung cancers, and correlate with an immune-engaged T cell profile. Oncoimmunology 2019;8:e1648170.